A primary focus for Basilea has been executing the objective to replenish its pipeline and provide longevity beyond the expected loss of exclusivity for its lead antifungal, Cresemba, in late 2027. While Cresemba continues to deliver exceptional performance—with global in-market sales exceeding $560m in 2024—the company is successfully transitioning to a multi-asset model driven by several important in-licensing deals and collaborations.
